Literature DB >> 15911136

The paradoxical effects of SKF83959, a novel dopamine D1-like receptor agonist, in the rat acoustic startle reflex paradigm.

Zhang-Jin Zhang1, Xiao-Long Jiang, Steven E Zhang, Christopher J Hough, He Li, Jian-Guo Chen, Xue-Chu Zhen.   

Abstract

While the benzazepine SKF83959 elicits classical behavioral responses associated with dopamine D1 receptors, it also acts as a D1 receptor antagonist biochemically. The paradoxical properties of this agent remain an enigma. In the present study, we sought to determine the behavioral effects of SKF83959 in the rat acoustic startle reflex test. Systemic administration of SKF83959 produced a dose-related increase in the startle amplitude with a stimulus of 105 dB, and a significant group difference was observed between animals treated with 1 mg/kg SKF83959 and vehicle controls. SKF83959 also significantly reduced the latency to startle response to stimuli of 95 dB and 105 dB in a dose-dependent manner. However, unlike classical dopamine D1-like receptor agonists, SKF83959 failed to disrupt prepulse inhibition (PPI) of either the startle amplitude or the latency to startle response; rather, the agent dose-dependently increased the PPI latency to startle response of 105 dB stimulus. These results suggest that the behavioral effects of SKF83959 in the rat acoustic startle reflex paradigm are paradoxical, and these paradoxical effects may be associated with its distinct pharmacological properties.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15911136     DOI: 10.1016/j.neulet.2005.03.001

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  7 in total

1.  SKF-83959 is not a highly-biased functionally selective D1 dopamine receptor ligand with activity at phospholipase C.

Authors:  Sang-Min Lee; Andrew Kant; Daniel Blake; Vishakantha Murthy; Kevin Boyd; Steven J Wyrick; Richard B Mailman
Journal:  Neuropharmacology       Date:  2014-06-12       Impact factor: 5.250

Review 2.  Heteromerization of G protein-coupled receptors: relevance to neurological disorders and neurotherapeutics.

Authors:  Laura Albizu; José L Moreno; Javier González-Maeso; Stuart C Sealfon
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-11       Impact factor: 4.388

3.  D1-D2 dopamine receptor synergy promotes calcium signaling via multiple mechanisms.

Authors:  Lani S Chun; R Benjamin Free; Trevor B Doyle; Xi-Ping Huang; Michele L Rankin; David R Sibley
Journal:  Mol Pharmacol       Date:  2013-05-16       Impact factor: 4.436

Review 4.  Dopamine D1 receptor signaling: does GαQ-phospholipase C actually play a role?

Authors:  Sang-Min Lee; Yang Yang; Richard B Mailman
Journal:  J Pharmacol Exp Ther       Date:  2014-07-22       Impact factor: 4.030

5.  Receptor heteromerization and drug discovery.

Authors:  Raphael Rozenfeld; Lakshmi A Devi
Journal:  Trends Pharmacol Sci       Date:  2010-01-07       Impact factor: 14.819

6.  Fabp7 maps to a quantitative trait locus for a schizophrenia endophenotype.

Authors:  Akiko Watanabe; Tomoko Toyota; Yuji Owada; Takeshi Hayashi; Yoshimi Iwayama; Miho Matsumata; Yuichi Ishitsuka; Akihiro Nakaya; Motoko Maekawa; Tetsuo Ohnishi; Ryoichi Arai; Katsuyasu Sakurai; Kazuo Yamada; Hisatake Kondo; Kenji Hashimoto; Noriko Osumi; Takeo Yoshikawa
Journal:  PLoS Biol       Date:  2007-11       Impact factor: 8.029

7.  Task-Dependent Effects of SKF83959 on Operant Behaviors Associated With Distinct Changes of CaMKII Signaling in Striatal Subareas.

Authors:  Pei-Pei Liu; Chih-Chang Chao; Ruey-Ming Liao
Journal:  Int J Neuropsychopharmacol       Date:  2021-09-21       Impact factor: 5.176

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.